July 23, 2019
Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% […]
July 12, 2019
BERLIN and SAN DIEGO, (GLOBE NEWSWIRE) — Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced today that it was selected by MedTech Outlook to receive the 2019 […]
June 18, 2019
Berlin (Germany), June 17, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its […]
June 4, 2019
Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, June 04, 2019 – Curetis N.V. (the “Company” and, together with Curetis GmbH and Curetis USA […]
May 23, 2019
Amsterdam, the Netherlands, and Holzgerlingen, Germany, May 23, 2019 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, […]
May 21, 2019
Berlin (Germany) and San Diego, CA (U.S.A.), May 20, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based […]
April 4, 2019
Growing body of evidence shows benefits of Unyvero for antibiotic stewardship 8 new reports on European studies presented by clinical researchers using Unyvero HPN, ITI, BCU […]
April 3, 2019
NEW YORK (GenomeWeb) Mar 26, 2019 – Vela Diagnostics has submitted a next-generation sequencing (NGS) assay that detects HIV-1 drug resistance mutations (DRMs) to the US […]
March 26, 2019
Menarini Diagnostics to distribute Unyvero Platform and application cartridges in numerous European countries Menarini Diagnostics to deploy its commercial team for the marketing of Unyvero Platform […]
